Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA EBITDA Margin
EBITDA as a percentage of revenue.
Intellia Therapeutics, Inc.NASDAQ: NTLA
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -624.9%
EBITDA Margin was -624.9% in Q1 FY2026, up 47.7 pp from a year earlier. On a trailing-twelve-month basis it was -581.9%, up 549.6 pp year over year. Over 3 fiscal years it widened by 308.9 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 13 analysts of -788.0% for the fiscal year ending Dec 2026, down from -586.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -624.9%-210.3 pp QoQ
- Last fiscal yearDec 2025
- -586.3%+292.7 pp YoY
- LTMMar 2026
- -581.9%+549.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -586.3%
- Year-over-year change
- +292.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -586.3% | +292.7pp |
| FY2024 | 2024-12-31 | -879.0% | +422.8pp |
| FY2023 | 2023-12-31 | -1301.8% | -406.5pp |
| FY2022 | 2022-12-31 | -895.3% | -105.6pp |
| FY2021 | 2021-12-31 | -789.6% | — |
EBITDA Margin vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 EBITDA Margin of -581.9% is the 5th highest of the 8 companies compared; the peer median is -258.7%.
- Its year-over-year change of +549.6 pp is the 3rd highest of 8, against a peer median of +387.8 pp.
- Over three fiscal years its change of +308.9 pp compares with a peer median of +435.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -40.5% | +584.3 pp | +435.7 pp | |
| LTM Mar 2026 | -120.0% | +290.8 pp | +619.2 pp | |
| LTM Jun 2026 | -167.8% | +2670.7 pp | -2283.2 pp | |
| LTM Mar 2026 | -258.7% | +387.8 pp | +719.4 pp | |
| LTM Mar 2026 | -581.9% | +549.6 pp | +308.9 pp | |
| LTM Mar 2026 | -713.8% | -30.6 pp | -622.8 pp | |
| LTM Mar 2026 | -999.5% | +475.3 pp | -608.7 pp | |
| LTM Sep 2026 | -1917.5% | -679.9 pp | +127741.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NTLA) | -258.7% | +387.8 pp | +435.7 pp | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.